Company Mount Magnet South Ltd Australian S.E.

Stocks

AU000000MUM1

Biotechnology & Medical Research

Business description: Mount Magnet South Ltd

Sales by Activity: Mount Magnet South Ltd

Geographical breakdown of sales: Mount Magnet South Ltd

Executive Committee: Mount Magnet South Ltd

Composition of the Board of Directors: Mount Magnet South Ltd

Shareholders: Mount Magnet South Ltd

Company details: Mount Magnet South Ltd

Bio Therapeutic Drugs

Sector

Inactive Instrument

End-of-day quote Australian S.E.
- ^AUD	-

08-25	Incannex Healthcare Doses First Patient In DReAMzz Phase 2 Study Of IHL-42X	CI
08-11	Incannex Healthcare Receives Additional AUD 5.1 Million R&D Tax Incentive Refund, Completing More Than AUD 11.2 Million In Non-Dilutive Capital Received In 2026	CI

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (USD)	2025 (USD)
R&D of the Use of Psychedelic Medicine and Therapies	-	-	-	12K	86K
Medicinal Cannabis	1.9M	782K	1.01M	-	-

See all business segments

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (USD)	2025 (USD)
Australia	1.9M	782K	1.01M	12K	86K

See all geographic segments

Manager	Title	Age	Since
Joel Latham CEO	Chief Executive Officer	37	01/01/2016
Joseph Swan DFI	Director of Finance/CFO	35	29/02/2024
Luigi Barbato CTO	Chief Tech/Sci/R&D Officer	63	21/10/2024
Parisa Asvadi CTO	Chief Tech/Sci/R&D Officer	-	01/01/2023
Lekhram Changoer CTO	Chief Tech/Sci/R&D Officer	60	05/07/2023

See MOUNT MAGNET SOUTH LTD governance

Director	Title	Age	Since
Troy Valentine CHM	Chairman	52	01/11/2023
Peter Widdows BRD	Director/Board Member	60	01/11/2023
Joel Latham BRD	Director/Board Member	37	01/01/2016
George Anastassov BRD	Director/Board Member	62	01/11/2023
Robert Clark BRD	Director/Board Member	66	01/11/2023

Composition of the Board of Directors

Name	Stocks	%	Valuation
Joel Latham 6.738 %	806,206	6.738 %	2 M $
Troy Valentine 3.438 %	411,290	3.438 %	1 M $
LPL Financial LLC 1.238 %	148,178	1.238 %	435 643 $
Millennium Management LLC 0.7961 %	95,252	0.7961 %	280 041 $
Global X Investments Canada, Inc. 0.7708 %	92,226	0.7708 %	271 144 $

List of MOUNT MAGNET SOUTH LTD shareholders

Incannex Healthcare, Inc.

8 Century Circuit

2153, Norwest

+61 4 0984 0786

http://www.incannex.com

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.41%	-2.07%	+41.26%	+95.40%	69.02B
ARGENX SE	-0.90%	+1.01%	+43.21%	+90.40%	66.32B
INSMED INCORPORATED	+0.04%	+4.36%	-11.72%	+459.54%	27.66B
BIONTECH SE	-0.90%	-7.65%	+2.45%	-15.50%	25.84B
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+39.40%	+9.41%	26.54B
GENMAB A/S	0.00%	+1.86%	+25.85%	-17.54%	20.4B
PHARMAESSENTIA CORPORATION	+3.45%	-13.46%	+222.69%	+389.50%	17.63B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-0.41%	+530.26%	15.15B
EXELIXIS, INC.	+1.03%	+7.00%	+59.98%	+160.03%	14.65B
Average	-0.15%	-1.37%	+46.97%	+189.06%	31.47B
Weighted average by Cap.	-0.28%	-0.83%	+41.75%	+148.40%

See all sector performances

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs